|
| 37221052 | Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. | J Neurol Neurosurg Psychiatry | 2023 |
| 36195775 | Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. | Journal of Neurology | 2023 |
| 38025317 | Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages. | | 2023 |
| 37743581 | Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy? | | 2023 |
| 37662038 | Neuroinflammatory disorders of the brain and inner ear: a systematic review of auditory function in patients with migraine, multiple sclerosis, and neurodegeneration to support the idea of an innovative 'window of discovery'. | Front Neurol | 2023 |
| 37640862 | The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. | | 2023 |
| 37695891 | Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment. | | 2023 |
| 37550942 | SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis. | | 2023 |
| 37282545 | Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. | Mult Scler | 2023 |
| 36969208 | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. | | 2023 |
| 37082445 | Editorial: CNS autoimmune disorders and COVID-19. | | 2023 |
| 37006492 | Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. | | 2023 |
| 37119056 | An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy. | | 2023 |
| 36619856 | Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. | | 2023 |
| 36611185 | Teriflunomide as a therapeutic means for myelin repair. | | 2023 |
| 37041077 | Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. | | 2023 |
| 34994579 | Body mass index as a predictor of MS activity and progression among participants in BENEFIT. | Multiple Sclerosis Journal | 2022 |
| 35775595 | Contribution of B cells to cortical damage in multiple sclerosis. | Brain | 2022 |
| 36370634 | Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. | EBioMedicine | 2022 |
| 36238285 | Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. | Frontiers in Immunology | 2022 |
| 35968288 | Case report: First case of neuromelioidosis in Europe: CNS infection caused by . | Frontiers in Neurology | 2022 |
| 35967385 | The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. | Frontiers in Immunology | 2022 |
| 35388213 | Vaccination and immunotherapies in neuroimmunological diseases. | Nature Reviews Neurology | 2022 |
| 36362063 | Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation. | International Journal of Molecular Sciences | 2022 |
| 35765217 | Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â¿¿years of follow-up in the DAYBREAK open-label extension trial. | Multiple Sclerosis Journal | 2022 |
| 35700670 | Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. | Multiple Sclerosis and Related Disorders | 2022 |
| 35378683 | Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. | | 2022 |
| 35378684 | The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. | | 2022 |
| 36001711 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. | N Engl J Med | 2022 |
| 36142246 | Modulation of Specific Sphingosine-1-Phosphate Receptors Augments a Repair Mediating Schwann Cell Phenotype. | International Journal of Molecular Sciences | 2022 |
| 36000489 | Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. | Multiple Sclerosis Journal | 2022 |
| 35367873 | The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. | Mult Scler Relat Disord | 2022 |
| 35674075 | Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. | Current Opinion in Neurology | 2022 |
| 35674067 | New drugs for multiple sclerosis: new treatment algorithms. | Current Opinion in Neurology | 2022 |
| 35674066 | Editorial: Advances in Multiple Sclerosis. | Current Opinion in Neurology | 2022 |
| 35608660 | Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. | Journal of Neurology | 2022 |
| 35480225 | Tissue donations for multiple sclerosis research: current state and suggestions for improvement. | Brain Communications | 2022 |
| 36325318 | Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. | Frontiers in Immunology | 2022 |
| 35668103 | Thinking outside the box: non-canonical targets in multiple sclerosis. | Nature Reviews Drug Discovery | 2022 |
| 35354603 | Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. | Neurology: Neuroimmunology and NeuroInflammation | 2022 |
| 36119682 | Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications. | Frontiers in Neurology | 2022 |
| 35981895 | An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort. | Neurology | 2022 |
| 36116382 | EBV and multiple sclerosis: Setting the research agenda. | Multiple Sclerosis and Related Disorders | 2022 |
| 35399125 | The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. | Journal of Neurology | 2022 |
| 36618356 | Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab. | | 2022 |
| 34240656 | Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. | Mult Scler | 2022 |
| 35266243 | Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. | Journal of the Peripheral Nervous System | 2022 |
| 34667130 | CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography. | Neurology: Neuroimmunology and NeuroInflammation | 2022 |
| 35246490 | Eculizumab versus rituximab in generalised myasthenia gravis. | Journal of Neurology, Neurosurgery and Psychiatry | 2022 |
| 35193952 | Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. | Journal of Neurology, Neurosurgery and Psychiatry | 2022 |